Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.

Carlo Gambacorti Passerini,Jeffrey H. Lipton,Andreas Hochhaus,Vamsi Kota,Michele Baccarani,Simon Durrant,Sarit Assouline,Dong-Wook Kim,Tim H. Brümmendorf,Eric Leip,Fiona An,Jean M. Aguiar,Jorge E. Cortes

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.

2018

Carlo Gambacorti Passerini
Jeffrey H. Lipton
Andreas Hochhaus
Vamsi Kota
Michele Baccarani
Simon Durrant
Sarit Assouline
Dong-Wook Kim
Tim H. Brümmendorf
Eric Leip
Fiona An
Jean M. Aguiar
Jorge E. Cortes

7062Background: Bosutinib has a distinct adverse event (AE) profile vs other TKIs used to treat Ph+ leukemia. Methods: Pts with chronic phase (CP) chronic myeloid leukemia (CML; n=403) or accelerat...

Keywords:

Pathology
Philadelphia Chromosome Positive
Tyrosine kinase
Cancer research
Bosutinib
Leukemia
Medicine
Oncology
in patient
Internal medicine
Myeloid leukemia
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations